Cooley Continues to Lead the Pack with Recent String of Life Sciences IPOs

Thirteen IPOs in this life-changing innovation space since June

Palo Alto – September 17, 2018 – Since June, Cooley has continued its leadership role in the life sciences IPO space, representing companies and underwriters on 13 IPOs during that short time frame. According to data from IPO Vital Signs, Cooley is the #1 law firm advising on issuer- and underwriter-side life sciences IPOs for Q2 2018.

“The momentum in the life sciences capital markets sector continues to be incredible,” said partner David Peinsipp, co-chair of Cooley’s capital markets practice alongside partner Charlie Kim, “and the pace has not slowed a bit heading into the end of the summer.” 

“Our teams continue to fire on all cylinders, partnering with these innovative companies and the investment banks advising them as they go public,” said Kim. “It truly is an exciting time to be working in a sector in which so much game-changing innovation is taking place.”

The deals include:

According to IPO Vital Signs and PitchBook data, Cooley is the #1 law firm for VC-backed IPOs across all industries over the last 10 years. Additionally, in 2017, Cooley ranked #1 for issuer-side IPOs across all industries, #1 for VC-backed IPOs across all industries, and #1 for all tech & life sciences IPOs. In 2017, Cooley advised on 136 completed capital markets transactions, including 30 IPOs. Moreover, Cooley is one of the top firms working on capital markets transactions for non-US private issuers.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.



Related Contacts
David Peinsipp Partner, San Francisco
Charlie Kim Partner, San Diego
Related Practices & Industries

Capital Markets Public Companies Life Sciences